Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$43,568
+$25,391 QoQ
Shares Held
278
+133.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,442
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Lavaca Capital LLC holds $11,294,866 across 14 Drug Manufacturers - General names. NVS ranks #10 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MRK |
Merck & Co., Inc.
|
65,773 | $8,451,830 | |
| 2 | ABBV |
AbbVie Inc.
|
2,819 | $709,373 | |
| 3 | LLY |
ELI LILLY & Co
|
486 | $582,923 | |
| 4 | JNJ |
Johnson & Johnson
|
2,093 | $531,559 | |
| 5 | AZN |
Astrazeneca PLC
|
1,648 | $312,493 | |
| 6 | PFE |
Pfizer Inc
|
10,873 | $261,821 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
1,489 | $188,120 | |
| 8 | BIIB |
Biogen Inc.
|
447 | $96,578 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43,568 | 278 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $18,177 | 119 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $16,406 | 119 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $15,260 | 119 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $14,400 | 119 | Shares | Sole | 2025-08-28 | |
| 2025-03-31 | $13,266 | 119 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $11,579 | 119 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||